Close
Nordic 9Nordic 9

AbbVie Ventures (investor - Corporate Investor)

United States abbvie.com
See something wrong or missing? Let us know
Offices:Chicago

AbbVie Ventures is the corporate venture capital group of AbbVie.

Average round investment:24.69M USD
Average number per year:1.0
Distribution: 2025 (1)2024 (1)2021 (1)
Portfolio companies: Denmark CephagenixGermany Disco PharmaceuticalsItaly Enthera Pharmaceuticals
Mostly invests in: Denmark Denmark (1) Pharma (3)

3 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to AbbVie Ventures

Name Criteria
China Zhejiang NHU
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Mayo Clinic
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Hx Bio Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Italy Alef 6
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma, Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Italy
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States YA II PN
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States 10X Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma, Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Global BioAccess Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma, Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Mike Jafar Family Office
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Japan Corundum Systems Biology
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Denmark Lars Hellerung Christiansen
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Pharma, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top